Allokin-alfa, lyophilizate 1 mg 3 pcs

Pharmacotherapeutic group: antiviral, immunomodulatory agent

ATX code J05AX, L03A

Pharmacological properties

Pharmacodynamics

Alloferon is an oligopeptide. By the nature of its pharmacological action it is the most similar to interferon alfa. Alloferon is an effective inducer of endogenous interferon synthesis and activator of natural killer system, it is able to stimulate recognition and lysis of defective cells by cytotoxic lymphocytes. High effectiveness against infections caused by influenza A and B viruses, hepatitis B and C, herpes types 1 and 2 and human papilloma has been demonstrated in experiments. Alloferon has no general toxicity, allergenic properties, mutagenic and carcinogenic action, does not have embryotoxic effect and does not affect reproductive function.

Pharmacokinetics

It quickly penetrates into the blood, where it interacts with immunocompetent cells, after which determination of Alloferon concentration is difficult due to the close structural similarity of its metabolites with serum proteins. The increased concentration of interferon was noted 2 hours after drug administration and remained at a high level (2-2.5 times higher than the usual background level) for 6-8 hours, reaching the baseline values by the end of the day. Increased functional activity of natural killers was observed for 7 days after the drug administration.

Indications

Active ingredient

Composition

Per 1 ampoule: Alloferon [Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine] 1.0 mg

How to take, the dosage

The drug is injected subcutaneously.
Standard course of treatment of infections caused by oncogenic types of human papilloma virus includes injections of the drug in a dose of 1 mg every other day, for a total of 6 injections.

Interaction

In the treatment of chronic recurrent genital herpes it can be prescribed in combination with acyclovir and its derivatives (the drugs have different mechanisms of action and complement each other in the treatment of viral infection). In acute hepatitis B the drug is prescribed against the background of generally accepted basic therapy.

The interaction with other medicinal products is not detected.

Special Instructions

In monotherapy Allokin-alpha is recommended for the treatment of papillomavirus infection caused by oncogenic types of the virus in the absence of clinical and subclinical lesions of the cervix and anogenital area.
As part of complex therapy – for the treatment of clinical and subclinical forms of cervical and anogenital lesions of papillomavirus infections caused by oncogenic virus types.
Treatment of chronic recurrent herpes types 1 and 2 is recommended to begin at the onset of the first symptoms.
For hepatitis B – not later than the 7th day after the appearance of jaundice.

Impact on ability to drive and operate machinery
If dizziness occurs, refrain from driving and operating machinery.

Synopsis

Contraindications

Hypersensitivity, pregnancy and breastfeeding (discontinue treatment), marked autoimmune diseases.

Childhood.

Side effects

In some cases, weakness, dizziness, formation of new rashes (in case of herpetic infection) may occur.

In some cases, weakness, dizziness, formation of new elements of the rash (in case of herpetic infection).

Overdose